Abstract 1014TiP
Background
Currently, 70%-80% of liver cancer patients have recurrence within 5 years after radical surgery. Therefore, determining effective treatment methods for liver cancer is still a major issue of global concern. Recombinant human adenovirus type 5 (rAd5, H101) is the world's first approved oncolytic virus product in China, rAd5 and transarterial chemoembolization (TACE) has significant anti-tumor effect in treatment of liver cancer. Compared with TACE, transhepatic arterial embolization (TAE) sequential thermal ablation may significantly improve the overall survival (OS) rate of liver cancer patients. This study aims to explore the efficacy and safety of rAd5 combined with TAE sequential thermal ablation in treatment of liver cancer, and to further explore the local and systemic immunological changes in patients.
Trial design
This is a prospective, open-label, randomized, parallel controlled study, 110 patients with medium- and high-risk recurrent liver cancer are expected to enroll. Key inclusion criteria are: age ≥18 and ≤70; ECOG performance status of 0-1; Child-Pugh score ≤7; and the expected survival time ≥3 months. All participants are randomized 1:1 to receive rAd5 combined with TAE and thermal ablation (experimental group) or TAE and thermal ablation (control group). Before, 10 mg dexamethasone was intravenously administered. rAd5 (H101) will be intratumorally injected into the hepatic segmental artery, the dosage is adjusted according to the maximum diameter of lesions: ≤10 cm, 1.0×1012 vp/day; ≥10 cm, 1.5×1012 vp/ day, 28 days for a cycle (4 cycles totally). 1-3 weeks after rAd5 injection and TAE or TAE, thermal ablation treatment will be performed if patients have residual tumor. Patients will be followed up at 1, 3, 6 and 12 months after treatment. The primary endpoint is objective response rate. Secondary endpoints include progression free survival, disease control rate, one-year OS and quality of life score. Exploratory endpoints are the changes from baseline in CD4+, CD8+, Treg, Th1 and Th2. The adverse events will be monitored.
Clinical trial identification
ChiCTR2300067319 (http://www.chictr.org.cn/); Release date, January 04, 2023.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
978P - Post-progression outcomes of advanced HCC patients (aHCC pts) treated with first-line atezolizumab/bevacizumab (A/B)
Presenter: Claudia Fulgenzi
Session: Poster session 18
979P - Safety interim analyses of first-line systemic therapy with atezolizumab plus bevacizumab (ATZ+BEV) in patients from Spain with unresectable hepatocellular carcinoma (HCC): Phase IIIb ATHECA
Presenter: Maria Elisa Reig Monzon
Session: Poster session 18
980P - Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma
Presenter: Young Mi Hong
Session: Poster session 18
981P - The response of portal vein tumoral thrombosis to moderately hypo-fractionated radiotherapy using intensity modulated radiotherapy
Presenter: Ahmad Abdel-Azeez
Session: Poster session 18
982P - Transarterial chemoembolization with idarubicin versus epirubicin for hepatocellular carcinoma: An interim analysis of a multicentre, randomized controlled phase III trial
Presenter: Zhewei Zhang
Session: Poster session 18
983P - Safety and efficacy of durvalumab plus hepatic artery infusion chemotherapy in HCC with severe portal vein tumor thrombosis (Vp3/4) – the DurHope study
Presenter: Ming Zhao
Session: Poster session 18
984P - Comparative study of scoring systems predicting outcome of transarterial chemoembolization for hepatocellular carcinoma: A nationwide cohort study
Presenter: Jo Kook Lee
Session: Poster session 18
987P - Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
Presenter: Wonseok Kang
Session: Poster session 18